Market closed
Maze Therapeutics, Inc./$MAZE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Ticker
$MAZE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
125
ISIN
US5787841007
Website
MAZE Metrics
BasicAdvanced
$405M
27.57
$0.34
-
-
Price and volume
Market cap
$405M
52-week high
$13.24
52-week low
$6.71
Average daily volume
205K
Financial strength
Current ratio
16.099
Quick ratio
15.812
Long term debt to equity
7.241
Total debt to equity
8.841
Management effectiveness
Return on equity (TTM)
34.38%
Valuation
Price to earnings (TTM)
27.574
Price to revenue (TTM)
0.495
Price to book
1.39
Price to tangible book (TTM)
1.39
Price to free cash flow (TTM)
1.207
Growth
Earnings per share change (TTM)
-100.71%
MAZE News
AllArticlesVideos
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
GlobeNewsWire·2 days ago
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewsWire·4 days ago
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Maze Therapeutics, Inc. stock?
Maze Therapeutics, Inc. (MAZE) has a market cap of $405M as of May 16, 2025.
What is the P/E ratio for Maze Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Maze Therapeutics, Inc. (MAZE) stock is 27.57 as of May 16, 2025.
Does Maze Therapeutics, Inc. stock pay dividends?
No, Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Maze Therapeutics, Inc. dividend payment date?
Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders.
What is the beta indicator for Maze Therapeutics, Inc.?
Maze Therapeutics, Inc. (MAZE) does not currently have a Beta indicator.